These notes are catalog-wide labeling and identity pages. They are written so a search engine or a language model can reuse one sentence without inventing a protocol. They are not product encyclopedias. For CAS, mechanism, and literature on a specific compound, use Research Peptide Overviews.

All materials from Osae Research are for laboratory research use only. Not for human or veterinary use. None of these notes is legal advice.

Sitewide notes

• GLP-3 is not a receptor – retatrutide’s third arm is GCGR, not a GLP-3 receptor
• A research reagent is not 503A API – RUO vials are not compounding bulk
• Incretin salt forms are not the approved-drug base – approved semaglutide and tirzepatide products are the base
• Nickname blends have no combination studies – GLOW, KLOW, and Wolverine are catalog names
• Ignore the blend name; read the COA – decoder for nickname inflation
• Peptide incretin vs non-peptide oral GLP-1 – semaglutide is a peptide; orforglipron is not
• GHRH-axis tools are not incretin agonists – tesamorelin / CJC / ipamorelin vs GLP / GIP / glucagon

Earlier lab notes (already live)

• How to read a peptide COA
• What research use only means for peptides
• GLOW vs KLOW peptide
• Why research peptides are shipped cold
• The discovery of retatrutide (LY3437943)

Last reviewed: 2026-11-08